As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg

Cancer Policy

After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster

A fraught Senate Finance Committee hearing, where HHS Secretary Robert F. Kennedy Jr. clashed with Republicans and Democrats alike, has led to some fallout.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

Cancer Policy

Vinay Prasad regains role as FDA chief medical and scientific officer

Vinay Prasad has regained his role as FDA’s chief medical and scientific officer, according to an update on the agency’s website.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

Cancer Policy

FDA advances rare disease drug development with new evidence principles

FDA introduced the Rare Disease Evidence Principles to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

Wistar Institute receives $17M NIH grant for personalized HIV cure research

The Wistar Institute has received an NIH granted, five-year $17 million research award to launch iCure Consortium to develop individualized “cure regimens” for HIV.

September 12, 2025

Vol.51 No.33

Podcast

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.

September 10, 2025

Vol.51 No.32

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

YOU MAY BE INTERESTED IN

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster

Vinay Prasad regains role as FDA chief medical and scientific officer

FDA advances rare disease drug development with new evidence principles

Wistar Institute receives $17M NIH grant for personalized HIV cure research

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

Renew today!

Subscriber content

Never miss an issue!

Login

As House committee gives NIH a small raise, cancer groups hope to maintain bipartisan support

YOU MAY BE INTERESTED IN

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”

After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster

Vinay Prasad regains role as FDA chief medical and scientific officer

FDA advances rare disease drug development with new evidence principles

Wistar Institute receives $17M NIH grant for personalized HIV cure research

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

Never miss an issue!

Login

The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.”